The Federal Circuit issued an opinion on July 29 affirming the District Court for the District of Delaware’s dismissal of Amgen Inc. and Amgen Manufacturing Ltd.’s (collectively, “Amgen”) complaint alleging infringement of U.S. Patent 8,273,707 (the “’707 Patent”) for failure to state a claim. The district court held that prosecution history estoppel barred Amgen from succeeding on its infringement claim under the doctrine of equivalents. Amgen Inc. v. Coherus BioSciences, Inc., No. 18-1993 (Fed Cir. July 29, 2019) (Before Reyna, Hughes, and Stoll, Circuit Judges) (Opinion for the Court, Stoll, Circuit Judge).
Federal Circuit Agrees That Argument-Based Prosecution Estoppel Barred Amgen from Succeeding on Infringement Claim
No Comments
Litigation
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung
- The Upshot of Google v. Oracle: An Absurd Ruling Will Lead to Absurd Results
- CAFC Dismisses Apple’s Bid to Overturn PTAB Holding it Failed to Prove Qualcomm Patents Obvious
Recent Posts
- Why the Patent Classification System Needs an Update
- Solutions for Promoting Patent Practitioner Diversity at the USPTO in the Battle Against Systemic Racism
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung